Compare iShares Core Growth Allocation ETF (AOR) vs Davita Inc (DVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs Davita Inc — how do they compare? iShares Core Growth Allocation ETF trades at $69.09, while Davita Inc trades at $232.88 (market cap $14.94B). Which is the better fit depends on your goals.
| AOR | DVA | |
|---|---|---|
52-Week High | $69.85 | $235.71 |
52-Week Low | $61.00 | $103.87 |
Market Cap | — | $14.94B |
Sector | — | Health |
Enterprise Value | — | $27.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares Core Growth Allocation ETF (AOR) trades at $69.10, up 0.25% on the day, with a bearish technical signal from moving averages and neutral oscillators. The fund maintains a fixed 60/40 stock/bond allocation, rebalanced semiannually, with a low 0.20% expense ratio. Recent news highlights its role as a core holding but notes underperformance versus the S&P 500 over a decade.
Outlook: AOR offers diversified, low-cost exposure but faces headwinds from equity-bond correlation shifts. Risks include interest rate sensitivity and competition from pure equity funds. Analyst sentiment is mixed, balancing simplicity against relative returns.
DaVita (DVA) trades at $232.80, up 1.45% on the day, with a bullish technical signal and strong institutional backing. Recent earnings show mixed quarterly beats, with Q1 2026 exceeding expectations. Revenue growth is steady, reaching $13.64B in 2025, though net income margin dipped to 5.47%. The stock is supported by positive analyst coverage and expansion in kidney care services, including AI-driven scheduling improvements. Current price sits near resistance at $233, with RSI levels indicating potential overbought conditions.
Outlook remains cautiously optimistic given DVA's market leadership and operational improvements, but high debt levels and valuation metrics pose risks. Analyst consensus suggests moderate upside to the $222.80 price target, with 39% buy ratings. Key risks include regulatory changes in healthcare and execution challenges in growth initiatives. The stock's proximity to yearly highs warrants monitoring for pullback opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
